Precision BioSciences: Innovating Gene Editing with ARCUS® and Advancing Genetic Medicine

Precision BioSciences: Leading the Charge in Gene Editing Innovation

Precision BioSciences, Inc., a clinical-stage gene editing company based in Durham, North Carolina, is at the forefront of advancing gene editing technologies through its proprietary ARCUS® platform. This innovative platform distinguishes itself by offering a smaller size and simpler structure compared to traditional gene editing methods, enabling more precise in vivo gene edits. The implications of this technology are significant, as it aims to address a wide range of genetic and infectious diseases that currently have limited therapeutic options. Precision BioSciences’ commitment to enhancing life through gene editing underscores its role as a key player in the biotechnology sector, particularly in the realm of genetic medicine.

The company highlights its dedication to innovation through participation in two notable upcoming investor conferences. The JonesTrading Virtual Genetic Medicine Day, set for November 25, 2024, will feature a panel discussion titled "Next Generation of Gene Editing; Going Beyond 'Cas.'" This event is particularly relevant as it showcases the evolution of gene editing technologies beyond the widely known CRISPR-Cas systems, emphasizing the potential of new methodologies like ARCUS. Additionally, Precision will present at the AussieMit conference on November 29, 2024, discussing "Emerging Therapies." Both events will provide a platform for Precision BioSciences to share insights about its advancements and engage with a broader audience interested in the future of genetic medicine.

In parallel with its conference activities, Precision BioSciences is actively enrolling patients in its ELIMINATE-B Phase 1 trial. This trial evaluates the efficacy of PBGENE-HBV, a candidate therapy aimed at treating hepatitis B. The company’s focus on clinical development demonstrates its commitment to translating innovative gene editing technology into viable treatment options. As the biotechnology landscape continues to evolve, Precision BioSciences remains dedicated to pioneering advancements in gene therapy, reinforcing its position as a leader in the industry.

In addition to its conference engagements and clinical trials, Precision BioSciences is keen on ensuring that its technological advancements reach those in need. The live webcast of the JonesTrading event will be available on the company’s website, along with an archived replay for those unable to attend in real-time. This commitment to accessibility reflects Precision’s ethos of transparency and engagement within the scientific and investment communities. For more information about the company's innovative approaches to gene therapy, stakeholders can visit their official website at www.precisionbiosciences.com.